BLUDE Immucor (MM)

NASDAQ DETERMINES IMMUCOR IN COMPLIANCE WITH ALL NASDAQ MARKETPLACE RULES NORCROSS, Ga., Nov. 15 /PRNewswire-FirstCall/ -- Immucor, Inc. (NASDAQ:BLUDE), the global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that it has been notified by The Nasdaq Stock Market, Inc. that the Company's common stock will resume trading under the symbol "BLUD" effective with the open of business on Wednesday, November 16, 2005. A Nasdaq Listing Qualifications Panel has determined that, in light of the Company's recent filing of its Form 10-Q for the period ended August 31, 2005, the Company has evidenced compliance with all Nasdaq Marketplace Rules. As a result, the Company's common stock will continue to be listed on the Nasdaq National Market and the fifth character "E" will be removed from the Company's trading symbol. Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at http://www.immucor.com/. Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor's expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as "plans," "expects," "believes," "anticipates," "estimates," "projects," "will," "should" and other words of similar meaning. Further risks are detailed in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on any forward-looking statements. Immucor assumes no obligation to update any forward-looking statements. DATASOURCE: Immucor, Inc. CONTACT: Edward Gallup of Immucor, Inc., +1-770-441-2051 Web site: http://www.immucor.com/

Copyright